Drugmaker Baxalta is working with bankers to buy a U.S.-based hematology and oncology specialist valued at about $2 billion.» Read More
*Biogen hemophilia A drug effective in trial. BOSTON, Oct 31- Biogen Idec Inc said on Wednesday its experimental treatment for patients with hemophilia A, a disorder that inhibits coagulation of the blood, controlled bleeding with fewer treatments in a late-stage clinical trial. Glenn Pierce, Chief Medical Officer for Biogen's hemophilia program.
Baxter International Inc. fell$. 82 or 1.3 percent, to $61.16. Bristol-Myers Squibb Co. fell$. 68 or 2.0 percent, to $33.36. Johnson& Johnson fell$. 82 or 1.1 percent, to $70.96.
Among the earnings stories for Thursday, Oct. 18, from AP Business News:. _ Morgan Stanley reported higher revenue and net income for its third quarter thanks to gains in its bonds and asset management businesses.
DEERFIELD, Ill.-- Drug and medical device maker Baxter International reported third-quarter results Thursday that edged 1 percent higher as the company trimmed expenses, meeting Wall Street expectations. The company's profit rose slightly to $583 million, or $1.06 per share, from $576 million, or $1.01 per share, in the prior-year period.
Oct 11- Baxter International Inc:. *PiperJaffray raises Baxter International price target to $73 from. Reuters Station users, click. 1568.
Oct 10- Baxter International Inc:. *Barclays raises Baxter International Inc price target to $63 from. Reuters Station users, click. 1568.
Oct 9- Baxter International Inc:. *Says expects to increase sales approximately 5 percent over its five-year long-range plan. *Sees generating cash flow from operations of approximately $4.5 billion by the year 2017.
Detailed results were revealed for the first time Monday at an American Neurological Association conference in Boston. "It's certainly not the home run we all wanted, but we're very encouraged by these results," said Maria Carillo, chief science officer for the Alzheimer's Association, which had no role in the research.
Take a look at some of Tuesday’s morning movers:
Cramer makes the call on viewers' favorite stocks.
Happy Friday! Take a look at some of this morning's early movers:
Culled from thousands of pages of 2012 outlook reports, 13 stocks are being called “The Most Recommended Stocks for 2012”, according to a new report from Birinyi Associates.
Mad Money's Jim Cramer interviews Kieran Gallahue, chairman and CEO of CareFusion.
It's still an open question whether stocks are heading into an extended bear market or if the severe pullback this summer from the highs in late April is a just correction phase in a larger bullish pattern.
Morningstar equity analyst Damien Conover is expecting healthier earnings for Johnson & Johnson than most analysts on Wall Street, he told CNBC Monday.
Despite all of the volatility and uncertainty of stocks, Baby Boomers heading into retirement are still better off with stocks than bonds, says a new analysis from Bank of America Merrill Lynch.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now! Also trading global auto sales.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Again, the wild action in the oil landed in the spotlight with potential weakness in energy among the rally’s biggest threats.
Baxter International is trying to fight its way back from a big crash last year, and yesterday (Monday), the bulls targeted more upside.